INBX
Inhibrx Biosciences Inc.- Healthcare
- Biotechnology
- $1.60B market cap
Forecast run · Sep 14, 2026Upside rank 409 of 3,136
Model Signal
ForecastQ Daily Probabilities
58.2%
66.9%
41.6%
Analyst Consensus
Recommendation2.40/5 Buy
Last price$109.27
Price target$285.00
Implied move+160.8%
Analysts5
ForecastQ Portfolios
INBX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.